RXFP1 receptor agonist-9

Cat. No.: HY-174334: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

RXFP1 receptor agonist-9 is a potent RXFP1 agonist with an EC₅₀ of 2.5 μM and Y_max of 65%. RXFP1 receptor agonist-9 exhibits good microsomal stability, reasonable PK and pharmacological activity. RXFP1 receptor agonist-9 can be used to the study of heart failure.

Para uso exclusivo en investigación. No vendemos a pacientes.

RXFP1 receptor agonist-9 Estructura química

No. CAS : 2924765-23-9

Tamaño		Stock
MOQ		Minimum order quantity
50 mg		Obtener un presupuesto
100 mg		Obtener un presupuesto
250 mg		Obtener un presupuesto
Other size		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Recomendaciones destacadas

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Parmacokinetics

Species	Dose	Route	T_1/2	AUC	V_ss	CL	F
Rat^[1]	1 mg/kg	i.v.	4.43 h	9.6 μM·h	0.09 L/kg	2.5 mL/min/kg	/
Rat^[1]	10 mg/kg	p.o.	/	/	/	/	6 %

In Vivo

RXFP1 receptor agonist-9 (Compound 39) (0.5-5 mg/min/kg, i.v., daily for 21 days) induces a dose-dependent heart rate increase (consistent with the hemodynamic profile of relaxin) in isoflurane-anesthetized naïve rats^[1].
RXFP1 receptor agonist-9 (25 mg/kg, i.v., respectively on day 6 and 7) elicites significant interpubic ligament (IPL) expansion, which recapitulated the effect of relaxin in C57BL/6 mouse^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Isoflurane-anesthetized male Sprague Dawley (SD) rat model
Dosage:	5 mg/min/kg
Administration:	IV, 60 min
Result:	Induced a 25% increase on heart rate.

Animal Model:	Isoflurane-anesthetized male Sprague Dawley (SD) rat model
Dosage:	0.5 mg/min/kg, 1.5 mg/min/kg, 5 mg/min/kg,
Administration:	Intravenous injection (i.v.), 60 min
Result:	Observed a dose-dependent increase at 1.5 and 5 mg/min/kg while no major effect was observed at 0.5 mg/min/kg.

Animal Model:	Baseline microCT scan acquired for the estrogen primed C57BL/6 female mice pubis (primed with estrogen on day 0)
Dosage:	25 mg/kg,
Administration:	IV, respectively on day 6 and 7
Result:	Showed 500% symphysis widening, and thus IPL expansion.

Peso molecular

727.67

Fòrmula

C₃₇H₃₄F₅N₃O₇

No. CAS

2924765-23-9

SMILES

O=C(N[C@@H]1[C@@H]2CC[C@H]([C@@H]1C(NC3=CC(C(F)(F)F)=C(C=C3)F)=O)/C2=C/C4CC4)C5=CC(C6=C(C=CC(C(C(O)=O)OC(NC)=O)=C6)F)=CC=C5OC

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Instrucciones de manejo (2659 KB)

Referencias

[1]. Su S et, al. The Discovery of C7-Substituted Norbornyl Bisamides as RXFP1 Small Molecule Agonists. J Med Chem. 2025 Jun 12;68(11):12185-12203. [Content Brief]